KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Total Liabilities (2016 - 2026)

Quest Diagnostics' Total Liabilities history spans 18 years, with the latest figure at $9.3 billion for Q1 2026.

  • On a quarterly basis, Total Liabilities rose 5.34% to $9.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $9.3 billion, a 5.34% increase, with the full-year FY2025 number at $9.1 billion, down 3.05% from a year prior.
  • Total Liabilities hit $9.3 billion in Q1 2026 for Quest Diagnostics, up from $9.1 billion in the prior quarter.
  • Over the last five years, Total Liabilities for DGX hit a ceiling of $9.3 billion in Q4 2024 and a floor of $6.7 billion in Q1 2023.
  • Historically, Total Liabilities has averaged $7.9 billion across 5 years, with a median of $7.5 billion in 2024.
  • Biggest five-year swings in Total Liabilities: dropped 4.57% in 2023 and later skyrocketed 31.84% in 2024.
  • Tracing DGX's Total Liabilities over 5 years: stood at $6.9 billion in 2022, then rose by 11.19% to $7.7 billion in 2023, then rose by 21.61% to $9.3 billion in 2024, then dropped by 3.05% to $9.1 billion in 2025, then grew by 2.78% to $9.3 billion in 2026.
  • Business Quant data shows Total Liabilities for DGX at $9.3 billion in Q1 2026, $9.1 billion in Q4 2025, and $8.9 billion in Q3 2025.